S. Gadgeel

Publications497
h-index61
Citations22,883
Highly Influential Citations941
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Shaw
  • 469 Publications • 47,884 Citations
  • D. Camidge
  • 604 Publications • 39,888 Citations
  • E. Felip
  • 861 Publications • 58,044 Citations
  • S. Ou
  • 340 Publications • 24,082 Citations
  • Publications
  • Influence
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
View on Elsevier
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
TLDR
In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum‐based drug resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
View on Wolters Kluwer
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer
TLDR
As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK‐positive NSCLC and independent review committee–assessed progression‐free survival were consistent with those for the primary end point.
View on Wolters Kluwer
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
View on PubMed
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
View on PubMed
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the…
View on PubMed
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
TLDR
Analysis of repeat biopsies from ALK-positive patients progressing on various ALK inhibitors finds that each ALK inhibitor is associated with a distinct spectrum of ALK resistance mutations and that the frequency of one mutation - ALK G1202R - increases significantly after treatment with second-generation agents.
View via Publisher
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
View on PubMed
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
View on PubMed
Rociletinib in EGFR-mutated non-small-cell lung cancer.
TLDR
Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation and the only common dose-limiting adverse event was hyperglycemia.
View on PubMed
...
...